Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine

By sjmartinez • April 27, 2023

Hendershot A, Slabaugh M, Riaz KM, Moore KN, O'Malley DM, Matulonis U, Konecny GE. Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine. Gynecol Oncol Rep. 2023 Feb 28;47:101155. doi: 10.1016/j.gore.2023.101155. PMID: 37102083; PMCID: PMC10123335.

Tags: Antibody-drug conjugates, Eye care, Folate receptor alpha, Hematology/Oncology, Mirvetuximab soravtansine, Ocular adverse events, ovarian cancer, Publications

Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial

Ueno M, Yoo C, Ren Z, Furuse J, Kelley RK, Chan SL, Edeline J, Klümpen HJ, Yau T, Verslype C, Ozaka M, Bouattour M, Park[...]

Brief Report: Combination Capmatinib and Trametinib in Metastatic MET-Driven NSCLC

Brown T, Lara MS, Jiang F, Garon EB, Goldman JW, Riess JW, Blakely CM. Brief Report: Combination Capmatinib and Trametinib in Metastatic MET-Driven NSCLC. JTO[...]

Susan Ettner, PhD and Dennis J. Slamon, MD, PhD Elected to the National Academy of Medicine

The UCLA Department of Medicine (DoM) is pleased to congratulate Susan Ettner, PhD and Dennis Slamon, MD, PhD, on their election to the National Academy[...]